Champions Oncology Inc (CSBR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $65.14M
Last updated: Nov 17, 2026 at 4:10 PM ET
Champions Oncology Inc (CSBR) Statistics
Champions Oncology (CSBR) has a market cap of $65.14M and an enterprise value of $60.78M. It earned -$1.14M on revenue of $60.66M over the last 12 months.
Total Valuation
Enterprise value is 6.69% below the market cap, as cash exceeds debt.
| Market Cap | $65.14M |
|---|---|
| Enterprise Value | $60.78M |
| Latest price (Nov 17, 2026) | $4.61 |
Key Dates
The next earnings report is expected on Dec 15, 2026, covering the quarter ending Oct 31, 2026.
| Next Earnings Date | Dec 15, 2026 (expected) |
|---|---|
| Last Earnings Date | Sep 10, 2026 |
| Fiscal Year End | April |
Valuation Ratios
Sales and book value multiples are 1.1x and 16.5x. Its year-end P/S ranged from 1.1x to 3.8x from 2016 to 2025.
| P/S Ratio | 1.1x |
|---|---|
| Forward P/S | 1.0x |
| P/B Ratio | 16.5x |
| P/TBV Ratio | 18.0x |
Enterprise Valuation
Counting debt and cash, the company is valued at 135.4x EBITDA.
| EV / Sales | 1.0x |
|---|---|
| EV / EBITDA | 135.4x |
Price Statistics
The stock is down 32.21% over 52 weeks and trades 5.53% below its 50-day average.
| Beta (1Y) | 0.38 |
|---|---|
| 52-Week Change | -32.21% |
| 1-Month Change | -1.71% |
| 3-Month Change | -6.68% |
| 6-Month Change | -22.91% |
| 5-Year Change | -50.77% |
| 10-Year Change | +204.43% |
| Total Return (1Y) | -32.21% |
| Total Return (3Y CAGR) | -5.54% |
| Total Return (5Y CAGR) | -13.87% |
| Return vs SPY (1Y) | -44.26% |
| Max Drawdown (1Y) | -40.90% |
| Max Drawdown (3Y) | -60.60% |
| Sharpe Ratio (1Y) | -0.75 |
| Correlation with SPY (1Y) | 0.10 |
| 50-Day Average | $4.88 |
| 200-Day Average | $5.60 |
| 52-Week Range | $4.52 to $8.31 |
| RSI (14 Days) | 38.8 |
| Average Volume (20 Days) | 7.23K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.03x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.03x |
|---|---|
| Quick Ratio | 1.03x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -29.15% and return on assets is -3.41% over the last 12 months.
| Return on Equity (ROE) | -29.15% |
|---|---|
| Return on Assets (ROA) | -3.41% |
| Return on Capital Employed (ROCE) | -6.13% |
| ROA (5Y Average) | -6.33% |
| ROIC (5Y Average) | 49.53% |
| Asset Turnover | 1.90x |
| Receivables Turnover | 4.53x |
Scores
CSBR has an Altman Z-Score of -0.34, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.34 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $60.66M over the last 12 months is up 6.65% from the 12 months before.
| Revenue | $60.66M |
|---|---|
| Revenue Growth (YoY) | +6.65% |
| Gross Profit | $30.22M |
| Operating Income | -$1.02M |
| Pretax Income | -$892.00K |
| Net Income | -$1.14M |
| EBITDA | $441.00K |
| EBIT | -$892.00K |
| Reported EPS (TTM) | -$0.04 |
Trailing 12 months through Jul 31, 2026.
Balance Sheet
Shareholder equity funds 11.69% of the $33.29M in total assets.
| Cash and Equivalents | $4.36M |
|---|---|
| Total Debt | $0 |
| Net Cash | $4.36M |
| Net Cash Per Share | $0.31 |
| Working Capital | $563.00K |
| Shareholder Equity | $3.89M |
| Book Value Per Share | $0.28 |
| Tangible Book Value | $3.56M |
| Tangible Book Per Share | $0.26 |
| Total Assets | $33.29M |
| Total Liabilities | $28.83M |
Balance sheet as of Jul 31, 2026.
Cash Flow
After $573.00K of capital spending, operating cash flow left -$6.14M of free cash flow.
| Operating Cash Flow | -$5.56M |
|---|---|
| Capital Expenditures | $573.00K |
| Free Cash Flow | -$6.14M |
| FCF Per Share | -$0.44 |
| Depreciation and Amortization | $1.33M |
Trailing 12 months through Jul 31, 2026.
Margins
The operating margin is -1.68%, against a 5-year average of -3.42%.
| Gross Margin | 49.82% |
|---|---|
| Operating Margin | -1.68% |
| Pretax Margin | -1.47% |
| Net Margin | -1.87% |
| EBITDA Margin | 0.73% |
| EBIT Margin | -1.47% |
| FCF Margin | -10.12% |
| Gross Margin (5Y Average) | 47.32% |
| Operating Margin (5Y Average) | -3.42% |
| Net Margin (5Y Average) | -3.40% |
Growth
Revenue grew 3.33% a year over 3 years.
| Revenue Growth (3Y CAGR) | +3.33% |
|---|---|
| Revenue Growth (5Y CAGR) | +7.68% |
| EPS Growth (5Y CAGR) | -24.40% |
Dividends and Yields
CSBR does not pay a dividend. Its free cash flow yield is -9.58%.
| FCF Yield | -9.58% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-12 reverse split on Aug 12, 2015.
| Last Split Date | Aug 12, 2015 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:12 |
Peer Position
Against 5 similar companies, CSBR has the lowest P/S.
P/S RatioPeer median 12.4x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -42.77%
| P/S Ratio | 1.1x vs 12.4x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +6.65% vs -42.77% median |
Analyst Forecast
Consensus estimates put revenue growth at 9.83% and EPS growth at 910.10% a year over the next fiscal year.
| Revenue Growth Forecast (1Y CAGR) | +9.83% |
|---|---|
| EPS Growth Forecast (1Y CAGR) | +910.10% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CSBR
What is CSBR's market cap?
Champions Oncology has a market cap of $65.14M. Its enterprise value, which adds debt and subtracts cash, is $60.78M.
How many shares of CSBR are outstanding?
Champions Oncology has 13.90M shares outstanding. The count is up 0.79% from a year earlier.
Does CSBR pay a dividend?
No. Champions Oncology does not pay a dividend.
How much debt does CSBR have?
Champions Oncology has $0 of total debt and $4.36M of cash and equivalents, a net cash position of $4.36M.
CSBR pages: Overview, Charting, Earnings, Financials, Statistics, Valuation, Competitors